Will the Public Plan Be Dropped to Save US Healthcare Reform?
This article was originally published in SRA
US healthcare reform has edged a little closer after the Senate voted to go ahead and debate its own consolidated reform bill. It is looking increasingly likely, however, that one of the central proposals – the controversial government-sponsored public health insurance scheme – may have to be jettisoned, or at least heavily diluted, if the reform is to pass Congress.
You may also be interested in...
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.